{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:58Z","timestamp":1793731078670,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>There is a need to establish which are the more relevant headache-related outcomes that have an impact on our patient\u2019s lives to accurately evaluate treatment response in daily clinical practice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>The aim of this study was to evaluate the relevance of clinical trial endpoints in clinical real-life disability improvement in response to migraine preventive treatment with OnabotulinumtoxinA.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This is an observational prospective study. We included patients with chronic migraine fulfilling ICHD-3beta\/3 criteria. We prospectively collected data of 8 headache-related and acute medication use endpoints recommended by the Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine. We evaluated their impact on disability improvement after 6\u2009months of treatment with OnabotulinumtoxinA. We defined as a responder in disability, patients with \u226550% MIDAS score reduction after 2\u2009cycles of treatment following PREEMPT protocol. We performed an analysis to measure the impact of improvement in the evaluated outcome measures according to perceived disability in clinical practice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We included 395 patients (85.1% women, mean age 46.7\u2009\u00b1\u200912.6\u2009years). Mean headache frequency at baseline was 26.5\u2009\u00b1\u20095.2 headache days\/month. After 6\u2009months, 49.1% of patients were headache-related disability responders. From all outcome measures collected, variables independently associated to disability improvement were headache days reduction (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and\u2009\u2265\u200950% pain intensity reduction (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). A\u2009\u2265\u200950% reduction in headache frequency or pain intensity showed similar influence on disability improvement after treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Headache pain intensity is as important as frequency when evaluating the clinical response and impact on patient headache-related disability after migraine preventive treatment with OnabotulinumtoxinA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s10194-020-01157-8","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T05:02:48Z","timestamp":1594443768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA"],"prefix":"10.1186","volume":"21","author":[{"given":"Marta","family":"Torres-Ferrus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Jos\u00e9","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"issue":"1","key":"1157_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15(1):70\u201378","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"1157_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 50(6):921\u2013936","journal-title":"Headache."},{"issue":"1","key":"1157_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-017-0784-4","volume":"18","author":"M Matharu","year":"2017","unstructured":"Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK (2017) The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain 18(1):78","journal-title":"J Headache Pain"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fneur.2018.00808","volume":"9","author":"E Caronna","year":"2018","unstructured":"Caronna E, Gallardo VJ, Hern\u00e1ndez-Beltr\u00e1n N, Torres-Ferrus M, Pozo-Rosich P (2018) OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse. Front Neurol 9:808","journal-title":"Front Neurol"},{"issue":"7","key":"1157_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3111\/13696998.2013.802694","volume":"16","author":"AJ Batty","year":"2013","unstructured":"Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW et al (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16(7):877\u2013887","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"1157_CR6","first-page":"45","volume":"35","author":"M Ruggeri","year":"2014","unstructured":"Ruggeri M (2014 May) The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(Suppl 1):45\u201347","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"5","key":"1157_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 38(5):815\u2013832","journal-title":"Cephalalgia."},{"issue":"9","key":"1157_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 33(9):629\u2013808","journal-title":"Cephalalgia."},{"issue":"1","key":"1157_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edition. Cephalalgia. 38(1):1\u2013211","journal-title":"Cephalalgia."},{"key":"1157_CR10","unstructured":"Pozo-Rosich P, Ezpeleta D (2015) In: Pozo-Rosich P, Ezpeleta D (eds) Gu\u00edas diagn\u00f3sticas y terap\u00e9uticas de la Sociedad Espa\u00f1ola de Neurolog\u00eda 2015. 3. Gu\u00eda oficial de pr\u00e1ctica cl\u00ednica en cefaleas, Luzan 5, Madrid"},{"issue":"7","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 30(7):804\u2013814","journal-title":"Cephalalgia."},{"issue":"5","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN et al (1999) An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology 53(5):988","journal-title":"Neurology"},{"issue":"9","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache. 41(9):854\u2013861","journal-title":"Headache."},{"issue":"6 Suppl 1","key":"1157_CR14","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1212\/WNL.56.suppl_1.S29","volume":"56","author":"J Edmeads","year":"2001","unstructured":"Edmeads J, L\u00e1inez JM, Brandes JL, Schoenen J, Freitag F (2001) Potential of the migraine disability assessment (MIDAS) questionnaire as a public health initiative and in clinical practice. Neurology. 56(6 Suppl 1):S29\u2013S34","journal-title":"Neurology."},{"issue":"10","key":"1157_CR15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/head.13638","volume":"59","author":"A Masters-Israilov","year":"2019","unstructured":"Masters-Israilov A, Robbins MS (2019) OnabotulinumtoxinA Wear-off phenomenon in the treatment of chronic migraine. Headache. 59(10):1753\u20131761","journal-title":"Headache."},{"issue":"10053","key":"1157_CR16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"T Vos","year":"2016","unstructured":"Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 388(10053):1545\u20131602","journal-title":"Lancet."},{"issue":"1","key":"1157_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11916-015-0533-9","volume":"20","author":"C Sun-Edelstein","year":"2016","unstructured":"Sun-Edelstein C, Rapoport AM (2016) Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep 20(1):1\u20138","journal-title":"Curr Pain Headache Rep"},{"issue":"10","key":"1157_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1046\/j.1526-4610.2003.03206.x","volume":"43","author":"JE Magnusson","year":"2003","unstructured":"Magnusson JE, Becker WJ (2003) Migraine frequency and intensity: relationship with disability and psychological factors. Headache J Head Face Pain 43(10):1049\u20131059","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1157_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-rosich P et al (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation. J Headache Pain 19(1):91","journal-title":"J Headache Pain"},{"issue":"8","key":"1157_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"AP Andreou","year":"2018","unstructured":"Andreou AP, Trimboli M, Al-kaisy A, Murphy M, Fenech C, Smith T et al (2018) A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K. technology appraisal. Eur J Neurol 25(8):1069\u20131e83","journal-title":"Eur J Neurol"},{"issue":"9","key":"1157_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, \u00c1fra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 16(9):968\u2013981","journal-title":"Eur J Neurol"},{"key":"1157_CR22","first-page":"1","volume-title":"Botulinum toxin type a for the prevention of headaches in adults with chronic migraine","author":"National Institute for Health and Clinical Excellence","year":"2016","unstructured":"National Institute for Health and Clinical Excellence (2016) Botulinum toxin type a for the prevention of headaches in adults with chronic migraine, pp 1\u201350"},{"issue":"6","key":"1157_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","volume":"52","author":"E Loder","year":"2012","unstructured":"Loder E, Burch R, Rizzoli P (2012) The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 52(6):930\u2013945","journal-title":"Headache."},{"issue":"4","key":"1157_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MFP Peres","year":"2007","unstructured":"Peres MFP, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N et al (2007) Patients\u2019 preference for migraine preventive therapy. Headache. 47(4):540\u2013545","journal-title":"Headache."},{"issue":"5","key":"1157_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 37(5):470\u2013485","journal-title":"Cephalalgia."},{"issue":"1","key":"1157_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 88(1):41\u201352","journal-title":"Pain."},{"issue":"suppl 1","key":"1157_CR27","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(suppl 1):S20\u2013S28","journal-title":"Neurology"},{"issue":"8","key":"1157_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JEJ, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974","journal-title":"Qual Life Res"},{"issue":"1","key":"1157_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1468-2982.2007.01461.x","volume":"28","author":"E Magnoux","year":"2008","unstructured":"Magnoux E, Freeman MA, Zlotnik G (2008) MIDAS and HIT-6 French translation: reliability and correlation between tests. Cephalalgia. 28(1):26\u201334","journal-title":"Cephalalgia."},{"issue":"3","key":"1157_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1526-4610.2009.01544.x","volume":"50","author":"KM Sauro","year":"2010","unstructured":"Sauro KM, Rose MS, Becker WJ, Christie SN, Giammarco R, Mackie GF et al (2010) HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache. 50(3):383\u2013395","journal-title":"Headache."},{"issue":"3\u20134","key":"1157_CR31","first-page":"39","volume":"10","author":"A Ghorbani","year":"2011","unstructured":"Ghorbani A, Chitsaz A (2011) Comparison of validity and reliability of the migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol 10(3\u20134):39\u201342","journal-title":"Iran J Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01157-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:05:44Z","timestamp":1625958344000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01157-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Vall d\u2019Hebron Ethics Committee. All patients gave their consent for data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors fully comply with and approve the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Torres-Ferrus M has received honoraria as speaker for Allergan, Chiesi, Novartis and Lilly. Gallardo VJ reports no disclosures. Alpuente-Ruiz A has received honoraria as speaker for Allergan. Pozo-Rosich P has received honoraria as a consultant and speaker for: Allergan, Almirall, Amgen, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva. Her research group has received research grants from Allergan, and has received funding for clinical trials from Alder, Electrocore, Eli Lilly, Novartis. She is a trustee member of the board of the International Headache Society, member of the Council of the European Headache Society. She is in the editorial board of Revista de Neurologia, associate editor for Cephalalgia, Neurologia, Frontiers of Neurology and Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of . Pozo-Rosich P does not own stocks from any pharmaceutical company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}